Ww. Mayosmith et al., NIR CONTRAST MATERIAL FOR VASCULAR ENHANCEMENT - VALUE OF SUPERPARAMAGNETIC IRON-OXIDE, American journal of roentgenology, 166(1), 1996, pp. 73-77
OBJECTIVE, The purposes of this study were to quantify abdominal vascu
lar enhancement and to prove the feasibility of iron oxide-enhanced MR
angiography in humans using three doses of superparamagnetic iron oxi
de agent AMI 227, SUBJECTS AND METHODS, Sixteen patients randomly rece
ived either 0.8, 1.1, or 1.7 mg Fe/kg of ultrasmall superparamagnetic
iron oxide agent AMI 227. T1-weighted breath-hold gradient-echo images
were obtained before and 45 min after IV administration of AMI 227, S
ignal intensity was measured in the aorta, the inferior vena cava, the
portal vein, and muscle on unenhanced and contrast-enhanced images, S
ignal-to-noise ratios acid enhancement [(SNR after contrast-SNR before
contrast) / SNR before contrast] were calculated, Vessels were visual
ly graded before and after administration of AMI 227. RESULTS. All ves
sels showed statistically significant enhancement 45 min, after admini
stration of AMI 227 by both qualitative and quantitative measures (p <
.001). There was no significant increase in noise or signal intensity
of muscle after contrast material was administered. The amount of enh
ancement was not statistically significantly different among the three
doses, CONCLUSION, AMI 227, which is currently in phase III clinical
trials, demonstrates significant vascular enhancement and may prove us
eful as an MR angiographic contrast agent.